(Press-News.org) Boston, MA – A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser Permanente Washington Health Research Institute highlights the challenges facing healthcare researchers and decision makers in the quest to improve population health in a constantly evolving healthcare landscape. The authors offer strategies to enhance the effectiveness of pragmatic clinical trials and increase their impact on real-world healthcare settings.
The Viewpoint appears October 2 in JAMA.
Pragmatic clinical trials, designed to inform health care decision-makers about the comparative benefits, burdens, and risks of health interventions, have seen a significant increase in interest over the past decade. Since 2012, the NIH Pragmatic Trials Collaboratory has supported 32 such trials, addressing critical issues like suicide prevention, opioid prescribing, and infection control.
Pragmatic clinical trials compare treatments in everyday clinical settings, rather than under ideal conditions. However, the authors note that the adoption of trial findings by healthcare systems has been inconsistent.
“Our goal is to ensure that the findings from these trials are not only scientifically sound but also readily implementable in diverse healthcare settings,” says lead author Richard Platt, Harvard Medical School distinguished professor of population medicine at the Harvard Pilgrim Health Care Institute. “Pragmatic clinical trials are designed to bridge the gap between research and care, and we believe this bridge can be built even more efficiently.”
The authors identify key challenges and propose solutions to align trial goals with healthcare system needs, including:
Identifying relevant outcomes: Collaborate with healthcare leaders to determine the clinical or cost-saving outcomes that would motivate adoption.
Shortening trial duration: Designing trials to span 2-3 years to match the decision-making timelines of healthcare systems.
Conducting interim assessments: Utilizing interim analyses to provide timely information and potentially stop or modify trials early.
Considering costs: Understanding and planning for associated costs to ensuring interventions are sustainable post-trial.
“By accommodating the priorities of healthcare leaders and introducing adaptive trial designs, we can generate actionable evidence that truly improves patient care,” adds Dr. Platt.
About the Harvard Pilgrim Health Care Institute’s Department of Population Medicine
The Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it is the first appointing medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and education, in partnership with health plans, delivery systems, and public health agencies. Point32Health is the parent company of Harvard Pilgrim Health Care and Tufts Health Plan. Follow us on X and LinkedIn.
END
Bridging the gap: how pragmatic trials can better serve healthcare systems
2024-10-02
ELSE PRESS RELEASES FROM THIS DATE:
UChicago scientists decode key mutation in many cancers
2024-10-02
Inside every cell, inside every nucleus, your continued existence depends on an incredibly complicated dance. Proteins are constantly wrapping and unwrapping DNA, and even minor missteps can lead to cancer.
A new study from the University of Chicago reveals a previously unknown part of this dance—one with significant implications for human health.
In the study, published Oct. 2 in Nature, a team of scientists led by UChicago Prof. Chuan He, in collaboration with University of Texas Health Science Center at ...
NYU Langone awarded $1.6 million to investigate Alzheimer’s & Parkinson’s progression through the eye
2024-10-02
Researchers at NYU Langone Health were awarded $1.6 million from the National Institutes of Health (NIH) to investigate changes in the eye that may indicate early signs of Alzheimer’s disease and Parkinson’s disease.
The award, OT2OD038130, recognizes the eye as a part of the brain and its role as a window into cognitive and visual health. After the initial $1.6 million award, the grant may renew an additional two years, for a total of $4.8 million as part of the NIH Common Fund Venture Program’s new Oculomics Initiative. Oculomics is a relatively new term to describe the integrative use of technology and ...
Missing link found in gamma emission phenomena from thunderclouds
2024-10-02
Groundbreaking Discoveries in Gamma-Ray Emissions from Thunderstorms
In the recent edition of Nature, groundbreaking results about the gamma-ray emissions produced during thunderstorms are presented. Overall, these findings reveal that gamma-ray emission from thunderclouds is much more complex, diverse, and dynamic than previously thought. Understanding these phenomena is crucial to uncovering the secrets of lightning.
Flickering Gamma-Ray Flashes: A New Discovery
Entitled “Flickering Gamma-Ray Flashes, the Missing Link between Gamma Glows and TGFs,” the paper by Østgaard et al. [2024] reports unique observations of a new phenomenon called Flickering Gamma-Ray ...
Social media users’ actions, rather than biased policies, could drive differences in platform enforcement
2024-10-02
A new paper, “Differences in misinformation sharing can lead to politically asymmetric sanctions,” published today in Nature suggests that the higher quantity of social media policy enforcement (such as account suspensions) for conservative users could be explained by the higher quantity of misinformation shared by those conservative users — and so does not constitute evidence of inherent biases in the policies from social media companies or in the definition of what constitutes misinformation.
Written by ...
How a bacterium becomes a permanent resident in a fungus
2024-10-02
Endosymbiosis is a fascinating biological phenomenon in which an organism lives inside another. Such an unusual relationship is often beneficial for both parties. Even in our bodies, we find remnants of such cohabitation: mitochondria, the powerhouses of our cells, evolved from an ancient endosymbiosis. Long ago, bacteria entered other cells and stayed. This coexistence laid the foundation for mitochondria and thus the cells of plants, animals, and fungi.
What is still poorly understood, however, is how an endosymbiosis as a lifestyle actually arises. A bacterium that more or less accidentally ...
Study: For long COVID, lithium aspartate at low doses is ineffective, but higher doses may be promising
2024-10-02
BUFFALO, N.Y. — A small University at Buffalo clinical trial has found that at low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of long COVID; however, a supplemental dose-finding study found some evidence that higher doses may be effective.
Published in JAMA Network Open on Oct. 2, the study was led by Thomas J. Guttuso, Jr., MD, professor of neurology in the Jacobs School of Medicine and Biomedical Sciences at UB and a physician with UBMD Neurology.
“It’s a negative study with a positive twist,” Guttuso concludes.
Because ...
Online insomnia treatment can help caregivers get much-needed rest, study suggests
2024-10-02
Providing care for a family member with a disabling illness can be a demanding job that leaves many people unable to sleep, but an online insomnia treatment developed at the University of Virginia School of Medicine can help, new research shows.
Not only did the SHUTi (Sleep Healthy Using the Internet) sleep intervention help caregivers get better rest, it most benefited those shouldering the greatest responsibilities in caring for their loved ones, the researchers found.
The results suggest the online format of the program ...
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies
2024-10-02
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies
The company is developing the biomaterial-based technology to develop novel therapies able to program anti-cancer immunity and prevent infectious diseases
By Benjamin Boettner
(BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Attivare Therapeutics Inc. announced that Attivare has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the ...
Regenstrief, Fairbanks researcher among 25 fellows to be inducted into American College of Medical Informatics
2024-10-02
The American College of Medical Informatics (ACMI) has announced that Chris Harle, PhD, of the Indiana University Richard M. Fairbanks School of Public Health and the Regenstrief Institute will be inducted as one of 25 new fellows on November 10 in San Francisco, CA, at ceremonies during the American Medical Informatics Association (AMIA) 2024 Annual Symposium.
ACMI is a college of elected fellows who have made significant and sustained contributions to the field of biomedical informatics. Individuals who have achieved national recognition in the field and are committed to advancing ...
Ontario Institute for Cancer Research funding aims to speed the development of new drugs for some of the most common cancers
2024-10-02
October 2, 2024, TORONTO – The Ontario Institute for Cancer Research (OICR) continues to support Ontario drug discovery research by funding high-quality investigations of new therapies for some of the most prevalent pediatric and adult cancers. These projects are tackling substantial challenges in cancer by increasing the effectiveness and availability of immunotherapies, making cancer more vulnerable to chemotherapy and developing a new drug for one of the deadliest forms of childhood brain cancer.
OICR’s Cancer Therapeutics Innovation Pipeline (CTIP) initiative is supporting three research teams ...